The Boston Ocular Surface Prosthesis as a Novel Drug Delivery System for Bevacizumab

REFERENCES

• Azar D. Corneal angiogenic privilege: Angiogenic and antiangiogenic factors in corneal avascularity, vasculogenesis, and wound healing. Trans Am Ophthalmol Soc 2006; 104: 264–302
   PubMedGoogle Scholar
• Cursiefen C, Maruyama K, Liu Y, et al. Inhibition of hem- and lymphangiogenesis after normal risk corneal transplantation by neutralizing VEGF promotes graft survival. Invest Ophthalmol Vis Sci 2004; 45: 2566–2673
   Google Scholar
• Dana R M, Streilein W J. Loss and restoration of immune privilege in eyes with corneal neovascularization. Investigative Ophthalmology and Visual Science 1996; 37(12)2485–2494
   PubMedGoogle Scholar
• Epstein R J, Stulting R D, Hendricks R L, et al. Corneal neovascularization: Pathogenesis and inhibition. Cornea 1987; 6(4)250–257
   PubMed Web of Science ®Google Scholar
• Epstein R J, Hendricks R L, Harris D M. Photodynamic therapy for corneal neovascularization. Cornea 1991; 10(5)424–432
   PubMedGoogle Scholar
• Chang J H, Gabison E E, Kato T, et al. Corneal neovascularization. Curr Opin Ophthalmol 2001; 12(4)242–249
   PubMed Web of Science ®Google Scholar
• Cursiefen C, Chen L, Saint-Geniez M, et al. Nonvascular VEGF receptor 3 expression by corneal epithelium maintains avascularity and vision. PNAS 2006; 103(30)11405–11410
   PubMed Web of Science ®Google Scholar
• Azar 2006, Philipp W, Expression of vascular endothelial growth factor and its receptors in inflamed and vascularized human cornea. IOVS 2000; 41: 2514–2522
   PubMed Web of Science ®Google Scholar
• Kvanta A, Sarman S, Fagerholm P, et al. Expression of matrix metalloproteinase-2 (MMP-2) and vascular endothelial growth factor (VEGF) in inflammation-associated corneal neovascularization. Exp Eye Res 2000; 70: 419–428
   PubMed Web of Science ®Google Scholar
• Amano S, Rohan R, Kuroki M, et al. Requirement for vascular endothelial growth factor in wound- and inflammation-related corneal neovascularization. Invest Ophthalmol Vis Sci 1998; 39: 18–22
   PubMed Web of Science ®Google Scholar
• Avery R L, Pieramici D J, Rabena M D, et al. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology 2005; 113: 363–372
   Google Scholar
• Avery R L. Regression of retinal and iris neovascularization after intravitreal bevacizumab (Avastin) treatment. Retina 2006; 26: 352–354
   PubMed Web of Science ®Google Scholar
• Rosenfeld P J, Fung A E, Puliafito C A. Optical coherence tomography findings after and intravitreal injection of bevacizumab (avastin) for macular edema from central retinal vein occlusion. Ophthalmic Surg Lasers Imaging 2005; 36: 336–339
   PubMed Web of Science ®Google Scholar
• Spaide R F, Fisher Y L. Intravitreal bevacizumab (Avastin) treatment of proliferative diabetic retinopathy complicated by vitreous hemorrhage. Retina 2006; 26: 275–278
   PubMed Web of Science ®Google Scholar
• Iliev M E, Domig D, Wolf-Schnurrbursch U, et al. Intravitreal bevacizumab (Avastin) in the treatment of neovascular glaucoma. Am J Ophthalmol 2006; 142: 1054–1056
   PubMed Web of Science ®Google Scholar
• Han Y S, Jung J W, Lee J S. Inhibitory effects of bevacizumab on angiogenesis and corneal neovascularization. Graefes Arch Clin Exp Ophthalmol, (in press)
   Google Scholar
• Manzano R P, Peyman G A, Khan P. Inhibition of corneal neovascularization by bevacizumab (Avastin). Br J Ophthal 2007; 91(6)804–807
   PubMed Web of Science ®Google Scholar
• Kim T I, Kim S W, Kim S. Inhibition of experimental corneal neovascularization by using subconjunctival injection of bevacizumab. Cornea 2008; 27(3)349–357
   PubMedGoogle Scholar
• Bock F, Onderka J, Dietrich T, et al. Bevacizumab as a potent inhibitor of inflammatory corneal angiogenesis and lymphangiogenesis. IOVS 2007; 48(6)2545–2552
   PubMed Web of Science ®Google Scholar
• Miltiadis P, Theodossiadis P G, Liarakos V S, et al. Inhibition of corneal neovascularization by subconjunctival bevacizumab in an animal model. Am J Ophthalmol 2008; 145: 424–431
   PubMedGoogle Scholar
• Erdurmus M, Totan Y. Subconjunctival bevacizumab for corneal neovascularization. Graefe's Arch Clin Exp Ophthlamol 2007; 245: 1577–1579
   PubMed Web of Science ®Google Scholar
• Carrasco M A. Subconjunctival bevacizumab for corneal neovascularization in herpetic stromal keratitis. Cornea 2008; 27(8)743–745
   PubMedGoogle Scholar
• Doctor P P, Bhat P V, Foster S C. Subconjunctival bevacizumab for corneal neovascularization. Cornea 2008; 27: 992–995
   PubMedGoogle Scholar
• DiStafeno J J, Kim T. Topical bevacizumab therapy for corneal neovascularization. Arch Ophthalmol 2007; 125(6)834–836
   PubMedGoogle Scholar
• Yoeruek E, Ziemssen F, Henke-Fahle S. Safety, penetration and efficacy of topically applied bevacizumab: evaluation of eyedrops in corneal neovascularization after chemical burn. Acta Ophthalmolgica 2008; 86: 322–328
   PubMed Web of Science ®Google Scholar
• Bock F, Konig Y, Kruse F, et al. Bevacizumab (Avastin) eye drops inhibit corneal neovascularization. Graefe's Archive for Clinical and Experimental Feb, 2008; 246(2)281–284
   PubMed Web of Science ®Google Scholar
• Uy H S, Chan P S, Ang R E. Topical bevacizumab and ocular surface neovascularization in patients with stevens-johnson syndrome. Cornea 2008; 27(1)70–73
   PubMedGoogle Scholar
• Kim S W, Ha B J, Kim E K, et al. The effect of topical bevacizumab on corneal neovascularization. Ophthalmology 2008; 115(6)e33–e88
   PubMedGoogle Scholar
• Jacobs D. Update on scleral lenses. Curr Opinion in Ophthalmol 2008; 19(4)298–301
   PubMedGoogle Scholar
• Romeo-Rangel T, Stavrou P, Cotter J, et al. Gas permeable scleral contact lens therapy in ocular surface disease. Am J Ophthalmology 2000; 130(1)25–32
   PubMedGoogle Scholar
• Kim S W, Ha B J, Kim E K, et al. The effect of topical bevacizumab on corneal neovascularization. Ophthalmology 2008; 115(6)e33–e88
   PubMedGoogle Scholar
• DeStefano J J, Kim T. Topical bevacizumab therapy for corneal neovascularization. Arch Ophthalmol 2007; 125(6)834–836
   PubMedGoogle Scholar
• Hurwitz H, Saini S. Bevacizumab in the treatment of metastatic colorectal cancer: safety profile and management of adverse events. Semin Oncol 2006; 3(5 Suppl 10)S26–S34
   Google Scholar